Sfoglia per AUTORE
QUACH H
Collezione AOU Città della Salute di Torino

  

Items : 5

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. in The New England journal of medicine / N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
2024
AOU Città della Salute di Torino

Moreau P; Bladé J; Rodriguez-Otero P; Carson R; de Boer CJ; Sitthi-Amorn A; Vanquickelberghe V; van Brummelen EMJ; Vieyra D; Wang J; Liu Y; Ahmadi T; Lonergan S; Jurczyszyn A; Hajek R; Spencer A; Einsele H; Vangsted A; Silzle T; Roeloffzen W; Delforge M; Rosiñol L; Sureda Balari A; Schjesvold F; Katodritou E; van de Donk NWCJ; Nijhof IS; Mina R; Gay F; et alii...

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma. in Future oncology (London, England) / Future Oncol. 2024;20(38):3043-3063. doi: 10.1080/14796694.2024.2394323. Epub 2024 Sep 17.
2024
AOU Città della Salute di Torino

Sonneveld P; Dimopoulos MA; Boccadoro M; Quach H; Ho PJ; Beksac M; Hulin C; Antonioli E; Leleu X; Mangiacavalli S; Perrot A; Cavo M; Belotti A; Broijl A; Gay F; Mina R; van de Donk NWCJ; Katodritou E; Schjesvold F; Balari AS; Rosiñol L; Delforge M; Roeloffzen W; Silzle T; Vangsted A; Einsele H; Spencer A; Hajek R; Jurczyszyn A; et alii...

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. in Transplantation and cellular therapy / Transplant Cell Ther. 2022 Jun;28(6):284-293. doi: 10.1016/j.jtct.2022.03.019. Epub 2022 Mar 17.
2022
AOU Città della Salute di Torino

Silberman R; Iftikhar R; Abonour R; Moreau P; Otero PR; Malhotra P; Biran N; Callander N; Janakiram M; Mohty M; Prince M; Beksac M; Chaudhry M; Aljurf M; Costa L; Hou J; Schriber J; Quach H; Einsele H; Cook G; Gay F; Costello C; Poudyal BS; Cowan A; Garfall A; Lonial S; Kumar A; Shah N; Kansagra A; et alii...

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. in The Lancet. Oncology / Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7.
2021
AOU Città della Salute di Torino

Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; et alii...

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2020 Dec 1;38(34):4030-4041. doi: 10.1200/JCO.20.02060. Epub 2020 Oct 6.
2020
AOU Città della Salute di Torino

Labotka R; Vorog A; Morgan G; Mateos MV; Iida S; Leleu X; Katodritou E; Chng WJ; Beksac M; Bringhen S; Garg M; Hájek R; Oriol A; Quach H; Špi?ka I; Dimopoulos MA; Wang B; Palumbo A; Lonial S;